


## E-SWIN is revolutionising the treatment of dry eyes

**E>EYE remedies the cause of the Sicca syndrome (dry eyes) and thus allows lasting treatment success.**

The dry-eye syndrome has become the second most common eye disease worldwide, due to the environmental influences and living conditions we are exposed to nowadays. Millions of people worldwide are affected by this disease, its symptoms and the limitations it imposes on their daily life. Standard treatments, however, often only result in a temporary improvement.

In 2014, with E>EYE, E-SWIN launched the first medical application on the ophthalmological market that treats the cause of dry eyes, the so-called Meibomian gland dysfunction, thus resulting in a lasting improvement. E>EYE is based on the regulated pulse light technology patented by E-SWIN (IRPL® - Intense Regulated Pulsed Light) and has been approved in more than 50 countries so far.

E>EYE is the first IPL technology worldwide that is specially certified for the treatment of Meibomian gland dysfunction.



### The dry-eye syndrome

The dry-eye syndrome already affects up to 20 % of the world population. 40 % of contact-lens and glasses wearers also experience the problem. Negative environmental influences and the modern ways of working and living encourage the syndrome. Current findings show that office employees and children are particularly vulnerable. Both groups are characterised by intensive use of digital screens. Redness, tiredness, blurred vision

and itchy eyes are the first clues, which can also develop very quickly into serious complications. The majority – around 80 % – of cases result from a dysfunction of the Meibomian glands: If the lipid layer in the tear film is too thin, the tear moisture evaporates too quickly, and the first symptoms begin.

Photo Credit: ©Shutterstock

## How does E>EYE work?

E-SWIN has revolutionised the treatment of dry eyes – with the key to this being IRPL® technology. On the contrary to standard IPL technology, IRPL® generates a new form of polychromatic pulse light and sends precisely calibrated, successive light impulses of various parametrisations. This significantly increases treatment success in comparison to classic IPL technology.

In the E>EYE treatment, flashes of light are transferred to the area around the eye and thus have an effect on the areas where the parasympathetic nerve runs.



Several neurological studies have proven that „lighting up“ the nerve slightly increases the temperature between the inner and outer Myelin sheath. This liberates neurotransmitters that interact with the Meibomian glands and stimulate gland secretion and contraction.

Consequently, the thin lipid layer receives a natural boost of lipids that reduces the evaporation of tear moisture and stops the eyes from drying out. The Meibomian glands can then properly function again, and the cause of the dry-eye syndrome is remedied.

The treatment with E>EYE is non-invasive, pain-free, simple, quick and usually results in immediate relief. The treatment includes three sessions, which each only last a few minutes. The treatment protocol includes 3 sessions (T0/T15/T45) – an optional 4<sup>th</sup> session (T75) may be

recommended or necessary.

85 % of patients note a positive effect of the treatment. In 62 % of cases, a long-lasting result of at least 6 months to 3 years is achieved. A 4<sup>th</sup> treatment is only necessary in 38 % of cases, and a single refresher treatment is recommended approximately once per year. Clinical studies that were conducted on over 400 test persons confirmed these results.

## E>EYE international sales

As a fully owned subsidiary of E-SWIN, ESW-Vision ([www.esw-vision.com](http://www.esw-vision.com)) has been responsible for international sales in the sector of ophthalmology and ophthalmic optics since 2017.

***“E>EYE is well-known as THE leading IPL technology for treating dry eyes, which gives 85 % of patients long-lasting relief!”***

Petra Bruckmüller, CEO/president of the E-SWIN group